PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 17, 2026Cancer Immunology Immunotherapy2 citationsOpen Access

Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2024

JHJingyi HouGMGuangyan MuZZZhuo Zhang

Key Points

  • The study aims to investigate the reporting frequencies of hematological and thrombotic adverse events associated with immune checkpoint inhibitor therapy.
  • Analyzed reporting data from the FDA Adverse Event Reporting System (FAERS) between 2014 and 2024.
  • Examined combination regimens for stronger reporting signals of adverse events.
  • Assessed the timelines of reporting and associated mortality rates.
  • Identified notable frequencies of hematological and thrombotic adverse events linked to immune checkpoint inhibitors.
  • Combination therapies showed significant signals for certain adverse events.
  • Early reporting and high mortality proportions emphasized the need for heightened clinical vigilance.

Abstract

Hematological and thrombotic AEs associated with ICI therapy show notable reporting frequencies in FAERS. Combination regimens demonstrated stronger reporting signals for certain events. These AEs frequently showed early reporting and notable mortality proportions, highlighting the importance of clinical vigilance. Further studies are needed to confirm these findings.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hou et al. (2026) studied this question.

synapsesocial.com/papers/69e1cf1b5cdc762e9d858030https://doi.org/10.1007/s00262-026-04380-5
Ask AI
Helpful
Bookmark
Share
View Full Paper